Work

Orbital decompression surgery among Medicare beneficiaries in the post‐teprotumumab era

Year: 2024

Type: article

Abstract: KEY POINTS: Utilization of orbital decompressions (ODS) increased (CAGR: +3.2%) from 2000 to 2019. FDA approved teprotumumab in January 2020; ODS utilization decreased (CAGR: -14.9%) from 2019 to 2022. In 2022, total spending was substantially higher for teprotumumab ($325 million) than surgery ($580,000).

Source: International Forum of Allergy & Rhinology

DOI: 10.1002/alr.23358

Authors: Akash M. Bhat, Zachary M. Soler, Rodney J. Schlosser, Ralph B. Metson, Vinay K. Rathi

Institutions: Medical University of South Carolina, Drexel University, Ralph H. Johnson VA Medical Center, Massachusetts Eye and Ear Infirmary, The Ohio State University

Language: English

Topic: Ophthalmology and Eye Disorders

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: National Institute on Deafness and Other Communication Disorders